{"id":8538,"date":"2019-09-24T10:51:08","date_gmt":"2019-09-24T14:51:08","guid":{"rendered":"https:\/\/www.silverlaw.com\/blog\/?p=8538"},"modified":"2019-09-24T10:51:08","modified_gmt":"2019-09-24T14:51:08","slug":"zynerba-pharmaceuticals-zyne","status":"publish","type":"post","link":"https:\/\/www.silverlaw.com\/blog\/zynerba-pharmaceuticals-zyne\/","title":{"rendered":"Silver Law Group Investigates Zynerba Pharmaceuticals (ZYNE)"},"content":{"rendered":"

\"SilverSilver Law Group is investigating Zynerba Pharmaceuticals (ZYNE), a publicly-traded company that is developing cannabinoid therapies for neuropsychiatric disorders, on behalf of investors in the company\u2019s stock.<\/p>\n

The investigation regards possible violations of federal securities laws by Zynerba officers and directors. Continue reading \u203a<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Silver Law Group is investigating Zynerba Pharmaceuticals (ZYNE), a publicly-traded company that is developing cannabinoid therapies for neuropsychiatric disorders, on behalf of investors in the company\u2019s stock. The investigation regards possible violations of federal securities laws by Zynerba officers and directors. Continue reading \u203a<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[602,590],"tags":[],"class_list":["post-8538","post","type-post","status-publish","format-standard","hentry","category-class-action","category-misrepresentation-and-omission-of-material-facts"],"yoast_head":"\nSilver Law Group Investigates Zynerba Pharmaceuticals (ZYNE)<\/title>\n<meta name=\"description\" content=\"Silver Law Group is investigating Zynerba Pharmaceuticals (ZYNE), a company that is developing cannabinoid therapies, on behalf of investors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.silverlaw.com\/blog\/zynerba-pharmaceuticals-zyne\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Silver Law Group Investigates Zynerba Pharmaceuticals (ZYNE)\" \/>\n<meta name=\"twitter:description\" content=\"Silver Law Group is investigating Zynerba Pharmaceuticals (ZYNE), a company that is developing cannabinoid therapies, on behalf of investors.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.silverlaw.com\/blog\/wp-content\/uploads\/2019\/08\/Pot4-300x200.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Silver Law Group\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silver Law Group Investigates Zynerba Pharmaceuticals (ZYNE)","description":"Silver Law Group is investigating Zynerba Pharmaceuticals (ZYNE), a company that is developing cannabinoid therapies, on behalf of investors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.silverlaw.com\/blog\/zynerba-pharmaceuticals-zyne\/","twitter_card":"summary_large_image","twitter_title":"Silver Law Group Investigates Zynerba Pharmaceuticals (ZYNE)","twitter_description":"Silver Law Group is investigating Zynerba Pharmaceuticals (ZYNE), a company that is developing cannabinoid therapies, on behalf of investors.","twitter_image":"https:\/\/www.silverlaw.com\/blog\/wp-content\/uploads\/2019\/08\/Pot4-300x200.jpg","twitter_misc":{"Written by":"Silver Law Group","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.silverlaw.com\/blog\/zynerba-pharmaceuticals-zyne\/","url":"https:\/\/www.silverlaw.com\/blog\/zynerba-pharmaceuticals-zyne\/","name":"Silver Law Group Investigates Zynerba Pharmaceuticals (ZYNE)","isPartOf":{"@id":"https:\/\/www.silverlaw.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.silverlaw.com\/blog\/zynerba-pharmaceuticals-zyne\/#primaryimage"},"image":{"@id":"https:\/\/www.silverlaw.com\/blog\/zynerba-pharmaceuticals-zyne\/#primaryimage"},"thumbnailUrl":"https:\/\/www.silverlaw.com\/blog\/wp-content\/uploads\/2019\/08\/Pot4-300x200.jpg","datePublished":"2019-09-24T14:51:08+00:00","author":{"@id":"https:\/\/www.silverlaw.com\/blog\/#\/schema\/person\/de64d999508b1ad10d608a99f0d2e752"},"description":"Silver Law Group is investigating Zynerba Pharmaceuticals (ZYNE), a company that is developing cannabinoid therapies, on behalf of investors.","breadcrumb":{"@id":"https:\/\/www.silverlaw.com\/blog\/zynerba-pharmaceuticals-zyne\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.silverlaw.com\/blog\/zynerba-pharmaceuticals-zyne\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.silverlaw.com\/blog\/zynerba-pharmaceuticals-zyne\/#primaryimage","url":"https:\/\/www.silverlaw.com\/blog\/wp-content\/uploads\/2019\/08\/Pot4-300x200.jpg","contentUrl":"https:\/\/www.silverlaw.com\/blog\/wp-content\/uploads\/2019\/08\/Pot4-300x200.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.silverlaw.com\/blog\/zynerba-pharmaceuticals-zyne\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.silverlaw.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Silver Law Group Investigates Zynerba Pharmaceuticals (ZYNE)"}]},{"@type":"WebSite","@id":"https:\/\/www.silverlaw.com\/blog\/#website","url":"https:\/\/www.silverlaw.com\/blog\/","name":"Securities Arbitration Lawyers Blog","description":"Published by Securities Arbitration Lawyers \u2014 Silver Law Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.silverlaw.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.silverlaw.com\/blog\/#\/schema\/person\/de64d999508b1ad10d608a99f0d2e752","name":"Silver Law Group","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.silverlaw.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9eb0a691642ae95c68ee1c45b5f50f35bae76a41f3d9f861c7bfd40c87661746?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9eb0a691642ae95c68ee1c45b5f50f35bae76a41f3d9f861c7bfd40c87661746?s=96&d=mm&r=g","caption":"Silver Law Group"}}]}},"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/posts\/8538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/comments?post=8538"}],"version-history":[{"count":1,"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/posts\/8538\/revisions"}],"predecessor-version":[{"id":8539,"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/posts\/8538\/revisions\/8539"}],"wp:attachment":[{"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/media?parent=8538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/categories?post=8538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/tags?post=8538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}